YTHDF2 and non-small cell lung carcinoma: Elevated levels of YTHDF1 and YTHDF2 correlate with a good survival outlook, more tumour‐infiltrating lymphocytes and PD‐L1 down‐regulation in NSCLC patients, suggesting their potential as prognostic markers and therapeutic targets related to the TIME in lung cancer.187